- Home
- S vs DNTH Comparison
S vs DNTH Comparison
Compare S & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | S | DNTH |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 6.5B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | S | DNTH |
|---|---|---|
| Price | $21.70 | $105.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 31 | 13 |
| Target Price | $19.28 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 6.8M | 652.5K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,001,278,000.00 | $2,036,000.00 |
| Revenue This Year | $22.84 | N/A |
| Revenue Next Year | $17.32 | $29.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.89 | N/A |
| 52 Week Low | $11.81 | $23.39 |
| 52 Week High | $23.95 | $117.88 |
Technical Indicators
Market Signals| Indicator | S | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 49.24 |
| Support Level | $14.37 | $100.00 |
| Resistance Level | N/A | $116.21 |
| Average True Range (ATR) | 1.02 | 4.39 |
| MACD | -0.20 | -0.94 |
| Stochastic Oscillator | 32.93 | 24.17 |
Price Performance
Historical ComparisonAbout S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.